Today, we took another step forward in our prostate cancer research, sharing positive topline results from our global trial for metastatic castration-resistant prostate cancer (mCRPC), a disease greatly in need of new solutions: on.pfizer.com/3M3jxMy
@AlbertBourla | 58,131 followers
Replying to @AlbertBourla
mCRPC is a form of advanced prostate cancer that impacts 10%-20% of men within a few years of their initial diagnosis. These patients need a solution, and we are working hard to target the disease in new, effective ways.

Engagement Map

Quotes
Replies
Retweets
Trendsmap

Retweeters

No retweeters found
5 retweeters not shown
For access to this functionality a Trendsmap Explore subscription is required.

A Trendsmap Explore subscription provides full access to all available timeframes

Find out more

Thanks for trying our Trendsmap Pro demo.

For continued access, and to utliise the full functionality available, you'll need to subscribe to a Trendsmap Pro subscription.

Find out more

This account is already logged in to Trendsmap.
Your subscription allows access for one user. If you require access for more users, you can create additional subscriptions.
Please Contact us if you are interested in discussing discounts for 3+ users for your organisation, or have any other queries.